Thermidas to address serious Diabetes battles in the Middle East

Type 2 Diabetes Mellitus is a well-known challenge in the Middle East region. The Finnish­ Thermidas and Novasvia in the United Arab Emirates enter the Health Care Thermal Imaging markets in the MENA region. The spearheads are from early diagnostics of diabetes complications to effective follow-up treatment.

The prevalence of Type 2 Diabetes among Emirati nationals is one of the highest in the world.  As reported by the International Diabetes Federation, already more than 17 % of the UAE’s population between the ages of 20 to 79 have Type 2 Diabetes. In the MENA region – countries such as Saudi Arabia, Bahrain, Kuwait, and Qatar – are facing the same issues as well.

Thermidas Thermal Imaging is an excellent medically certified tool for many diabetic problems such as Charcot foot, neuro-ischemia, neuropathy, and infection detection. Early detection is essential in creating a successful treatment plan and can furthermore improve patient outcomes.

Novasvia has been involved in the healthcare sector for the last 30 years. Managing Partner of Novasvia Dr. Abeer Zarour is looking forward to the co-operation with Thermidas, and comments:

“As the number of diabetics in the MENA region is expected to reach 95 million by 2030, thermal imaging has the potential to help medical practitioners by minimizing the number of avoidable complications.”

“Our regional market entry programs are very well applied for the health care sector, and initially, our partners throughout the MENA region are interested in Thermidas solutions.”

Thermidas CEO Raimo Mansikkaoja summarizes:

“Thermidas has developed solutions for capturing and analyzing thermal images for over 10 years. The clinically tested solutions are currently being used in private clinics from university hospitals.”

“Novasvia has already a vast network and experience in the MENA region. It gives Thermidas a natural choice for reaching potential users quickly and efficiently.”